Provention Bio Profit Margin

The latest profit margin for PRVB is -876.11% as of December 2022. That compares with -8203.01% in the prior-year period — up 89.3% year over year. That is below the Healthcare sector average of 9.71%. Investors often review this figure alongside Provention Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRVB's profit margin moved from -8203.01% to -876.11% — a 89.3% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Provention Bio's valuation or profitability profile.

Against Healthcare companies, PRVB currently prints -876.11% for profit margin, while the sector average sits near 9.71%. That is roughly 9126.4% below the sector mean. Large gaps often invite a closer look at Provention Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Provention Bio converts resources into returns. At -876.11%, PRVB may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -8203.01% in the prior-year period — up 89.3% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PRVB's profit margin (-876.11%), review year-over-year change from -8203.01%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.